Current Headlines

  1. Newron Receives Complete Response Letter From US FDA For Xadago (safinamide)
    3/29/2016

    Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partners Zambon S.p.A. and US WorldMeds announced recently that a complete response letter from the FDA has been received for safinamide

  2. Significant Unmet Medical Needs Accelerating The Growth Of The Global Acne Drugs Market, Says Technavio
    3/25/2016

    According to the latest research study released by Technavio, the global acne drugs market is expected to reach close to USD reach USD 4.4 billion by 2020

  3. NantWorks And UCLA Researchers Develop Method To Achieve High Accuracy Classification Of Cancer Cells In Native Form
    3/24/2016

    Researchers at the University of California, Los Angeles (UCLA) Department of Electrical Engineering in collaboration with scientists from NantWorks, LLC recently announced they have developed a new cell diagnostics method that has the potential to open up a new path to data-driven cancer diagnostics and drug development

  4. Certara’s Synchrogenix Division Provides Unique Technology Solution, Enabling Biopharma Companies To Comply With EMA Policy 70
    3/24/2016

    Certara, the global biosimulation technology-enabled drug development company, recently announced that its regulatory and medical consultancy, Synchrogenix, has introduced an artificial intelligence (AI) -enabled solution to meet the data transparency requirements of the clinical and drug development market

  5. Bristol-Myers Squibb To Acquire Padlock Therapeutics, Inc.
    3/23/2016

    Bristol-Myers Squibb Company and Padlock Therapeutics, Inc. announced recently that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases

  6. Ablexis Announces Perpetual License Of The AlivaMab Mouse To A Top 15 Pharma
    3/22/2016

    2, 2016 – Ablexis, LLC announced recently the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company

  7. Librede Receives Phase I SBIR To Develop Yeast-Based Cannabinoid Production And Drug Discovery Platform
    3/22/2016

    Librede, a biotechnology company specializing in yeast-based cannabinoid production, announced that it has received a Small Business Innovative Research (SBIR) grant from the National Center for Complementary & Integrative Health (NCCIH) of the National Institutes of Health (NIH)

  8. Reset Therapeutics, Inc. Establishes Research Collaboration With Alkermes For Discovery And Development Of Novel Orexin Modulators
    3/17/2016

    Reset Therapeutics, Inc., announced recently a collaboration with an affiliate of Alkermes plc for the discovery, development and commercialization of novel orexin receptor modulators from Reset’s drug discovery platform

  9. Allied-Bristol Life Sciences Launches iβeCa Therapeutics From NYU School Of Medicine To Develop Novel Cancer Therapeutics Targeting The Wnt Pathway
    3/16/2016

    Allied-Bristol Life Sciences, LLC (ABLS), a biopharmaceutical enterprise jointly owned between Allied Minds and Bristol-Myers Squibb Company, announced that it has launched a new subsidiary, iβeCa Therapeutics, to license proprietary compounds from NYU School of Medicine that target the Wnt signalling pathway

  10. Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval Of EVOMELA (melphalan) For Injection
    3/15/2016

    Ligand Pharmaceuticals Incorporated announces thatSpectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) of EVOMELA